Divarasib

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

13 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 1 Phase I/II: 1

Oversight events:

1 serious breach 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 4

All trials

4 total

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Phase III 12 countries F. Hoffmann-La Roche AG
A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici… Recruiting

2023-507171-22-00 Phase I/II 6 countries F. Hoffmann-La Roche AG
A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting

2023-504263-16-00 Phase III 4 countries F. Hoffmann-La Roche AG
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG

Showing 1–4 of 4 trials

← All drugs A–Z